Mary Eileen Dolan

Research Summary
The Dolan lab is focused on improving the quality of life of cancer patients through the identification of genetic variants associated with risk for severe and persistent toxicities following chemotherapy (i.e. peripheral neuropathy, ototoxicity, tinnitus), particularly in children and young adults whose adverse sequelae could persist throughout their lifetimes. To this end, they perform clinical genome wide association studies to identify genetic variants associated with toxicity in patients following chemotherapy and determine whether there is shared genetic architecture with idiopathic forms of these traits. They develop preclinical models to elucidate the biochemical and cellular impact of genes identified in clinical studies of chemotherapeutic toxicity. Their approach integrates multiple large datasets including: genetic variation, gene expression, miRNA, modified cytosine, transcription factor levels and chemotherapeutic induced pharmacologic traits. Her laboratory made the seminal observation that chemotherapeutic-induced cytotoxicity is a heritable trait and that pharmacologic SNPs, identified through GWAS, are enriched in expression quantitative trait loci. More recently, her laboratory has developed an induced pluripotent stem cell derived neuronal cell model to evaluate genes contributing to chemotherapeutic-induced neuropathy, a common adverse event of multiple chemotherapeutic agents. They are creating a resource of human induced pluripotent stem cell derived neurons from well-phenotyped cancer survivors following treatment with paclitaxel, vincristine or cisplatin to be used to identify an in vitro toxicity readout that parallels the clinical phenotype. The models they are developing will have broad applicability for gaining insight on druggable targets to treat or prevent this devastating side effect of chemotherapy and providing an understanding of the genetic components and genes contributing to severe toxicity.
Pharmacogenomics, Antineoplastic Agents, Genome Wide Association Studies, Toxicities, Drug, IPS Cells
  • University of Dayton, Dayton, OH, BS Chemistry 04/1979
  • Purdue University, West Lafayette, IN, PHD Medicinal Chemistry 12/1983
  • Pennsylvania College of Medicine, Hershey, PA, Post Doc Biochemical Pharmacology 01/1986
Biosciences Graduate Program Association
Awards & Honors
  • 2005 - Presidential Award for Volunteer Contributions to Research American Cancer Society, IL Division
  • 2006 - Ambassador of Hope American Cancer Society
  • 2006 - Distinguished Alumni Award University of Dayton
  • 2010 - School of Pharmacy Distinguished Alumni Award Purdue University
  • 2011 - Distinguished Women Scholars Award Purdue University
  • 2016 - Biological Sciences Division Distinguished Educator/Mentor University of Chicago
  1. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023 Feb; 17(1):27-39. View in: PubMed

  2. Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer. Cancer Med. 2023 02; 12(3):2999-3012. View in: PubMed

  3. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816. View in: PubMed

  4. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021 Nov 01; 127(21):4091-4102. View in: PubMed

  5. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021 07; 14(4):1490-1504. View in: PubMed

  6. Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum Mol Genet. 2021 04 26; 30(3-4):305-317. View in: PubMed

  7. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558. View in: PubMed

  8. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. View in: PubMed

  9. Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women. Cancer Med. 2020 06; 9(11):3714-3724. View in: PubMed

  10. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897. View in: PubMed

  11. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924. View in: PubMed

  12. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. J Natl Compr Canc Netw. 2019 05 01; 17(5):459-468. View in: PubMed

  13. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clin Cancer Res. 2019 07 01; 25(13):4104-4116. View in: PubMed

  14. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155. View in: PubMed

  15. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190. View in: PubMed

  16. Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep. 2018 01 15; 8(1):733. View in: PubMed

  17. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018 Feb; 168(1):207-220. View in: PubMed

  18. Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. J Proteome Res. 2017 11 03; 16(11):4227-4236. View in: PubMed

  19. Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res. 2017 07; 22:79-88. View in: PubMed

  20. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768. View in: PubMed

  21. Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019. View in: PubMed

  22. Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3). View in: PubMed

  23. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333. View in: PubMed

  24. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol. 2016 08 10; 34(23):2712-20. View in: PubMed

  25. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. View in: PubMed

  26. Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Res. 2016 Jan; 16(1):140-8. View in: PubMed

  27. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol. 2016 Jan; 140(1):176-83. View in: PubMed

  28. Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics. 2015; 10(9):810-8. View in: PubMed

  29. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46. View in: PubMed

  30. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metab Dispos. 2015 Jul; 43(7):1084-90. View in: PubMed

  31. SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database (Oxford). 2015; 2015. View in: PubMed

  32. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015 Feb 24; 313(8):815-23. View in: PubMed

  33. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One. 2015; 10(2):e0118020. View in: PubMed

  34. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8. View in: PubMed

  35. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208. View in: PubMed

  36. Linking the genetic architecture of cytosine modifications with human complex traits. Hum Mol Genet. 2014 Nov 15; 23(22):5893-905. View in: PubMed

  37. Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol. 2014 Jul; 38(5):402-15. View in: PubMed

  38. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192. View in: PubMed

  39. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106(5). View in: PubMed

  40. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics. 2014 May; 24(5):231-7. View in: PubMed

  41. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther. 2014 May; 13(5):1334-44. View in: PubMed

  42. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52. View in: PubMed

  43. EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220. View in: PubMed

  44. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66. View in: PubMed

  45. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7. View in: PubMed

  46. Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics. 2013 Oct 01; 45(19):877-88. View in: PubMed

  47. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics. 2013 Aug; 194(4):987-96. View in: PubMed

  48. Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet. 2012; 3:202. View in: PubMed

  49. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20. View in: PubMed

  50. Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics. 2013 Apr; 14(5):447-50. View in: PubMed

  51. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76. View in: PubMed

  52. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393. View in: PubMed

  53. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9. View in: PubMed

  54. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9. View in: PubMed

  55. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med. 2012; 4(11):90. View in: PubMed

  56. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34. View in: PubMed

  57. Variants affecting exon skipping contribute to complex traits. PLoS Genet. 2012; 8(10):e1002998. View in: PubMed

  58. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther. 2012 Oct; 92(4):425-7. View in: PubMed

  59. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73. View in: PubMed

  60. Relating human genetic variation to variation in drug responses. Trends Genet. 2012 Oct; 28(10):487-95. View in: PubMed

  61. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):E2343-52. View in: PubMed

  62. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55. View in: PubMed

  63. Regulatory polymorphisms in ?-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2012 Aug 15; 18(16):4441-8. View in: PubMed

  64. Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res. 2012 May 15; 18(10):2791-800. View in: PubMed

  65. Systems and genome-wide approaches unite to provide a route to personalized medicine. Genome Med. 2012; 4(3):29. View in: PubMed

  66. Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics. 2012 Jul; 22(7):498-507. View in: PubMed

  67. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525. View in: PubMed

  68. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics. 2012 Jan; 13(1):55-70. View in: PubMed

  69. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80. View in: PubMed

  70. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43. View in: PubMed

  71. Genetics and variable drug response. JAMA. 2011 Jul 20; 306(3):306-7. View in: PubMed

  72. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920. View in: PubMed

  73. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res. 2011 Sep 01; 17(17):5748-54. View in: PubMed

  74. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23. View in: PubMed

  75. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500. View in: PubMed

  76. Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug; 8(4):692-701. View in: PubMed

  77. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88. View in: PubMed

  78. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46. View in: PubMed

  79. Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res. 2008; 4:1-13. View in: PubMed

  80. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. View in: PubMed

  81. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011 Jun; 12(5):487-97. View in: PubMed

  82. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. View in: PubMed

  83. The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95. View in: PubMed

  84. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80. View in: PubMed

  85. The emerging role of microRNAs in drug responses. Curr Opin Mol Ther. 2010 Dec; 12(6):695-702. View in: PubMed

  86. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33. View in: PubMed

  87. Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One. 2010 Oct 21; 5(10):e13534. View in: PubMed

  88. Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med. 2008 Nov; 2008(1):7-14. View in: PubMed

  89. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010 Aug 04; 102(15):1114-30. View in: PubMed

  90. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010 May 18; 107(20):9287-92. View in: PubMed

  91. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010 Apr 01; 6(4):e1000888. View in: PubMed

  92. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4. View in: PubMed

  93. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr; 20(4):269-73. View in: PubMed

  94. Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One. 2010 Feb 23; 5(2):e9366. View in: PubMed

  95. Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Curr Bioinform. 2008 Sep 01; 3(3):178. View in: PubMed

  96. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12. View in: PubMed

  97. Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics. 2010 Feb; 11(2):249-56. View in: PubMed

  98. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009 Dec; 61(4):413-29. View in: PubMed

  99. Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics. 2009 Dec; 10(12):1897-903. View in: PubMed

  100. SCAN: SNP and copy number annotation. Bioinformatics. 2010 Jan 15; 26(2):259-62. View in: PubMed

  101. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95. View in: PubMed

  102. Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biol. 2009; 9(3):55-63. View in: PubMed

  103. A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics. 2009 Oct; 19(10):829-32. View in: PubMed

  104. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42. View in: PubMed

  105. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14. View in: PubMed

  106. Etoposide pathway. Pharmacogenet Genomics. 2009 Jul; 19(7):552-3. View in: PubMed

  107. Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol. 2009 Sep-Oct; 6(4):412-25. View in: PubMed

  108. The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol. 2009 May 15; 77(10):1586-92. View in: PubMed

  109. Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics. 2009 Apr; 10(4):549-63. View in: PubMed

  110. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14. View in: PubMed

  111. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89. View in: PubMed

  112. FstSNP-HapMap3: a database of SNPs with high population differentiation for HapMap3. Bioinformation. 2008; 3(3):139-41. View in: PubMed

  113. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009 Jan; 3(2):128-42. View in: PubMed

  114. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53. View in: PubMed

  115. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80. View in: PubMed

  116. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet. 2009 Feb; 125(1):81-93. View in: PubMed

  117. Exploring the evolutionary history of the differentially expressed genes between human populations: action of recent positive selection. Evol Bioinform Online. 2008 May 15; 4:171-9. View in: PubMed

  118. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun; 64(1):133-42. View in: PubMed

  119. Population-specific GSTM1 copy number variation. Hum Mol Genet. 2009 Jan 15; 18(2):366-72. View in: PubMed

  120. SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation. 2008 Aug 01; 2(10):469-70. View in: PubMed

  121. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther. 2008 Sep; 7(9):3038-46. View in: PubMed

  122. HapMap filter 1.0: a tool to preprocess the HapMap genotypic data for association studies. Bioinformation. 2008 May 13; 2(8):322-4. View in: PubMed

  123. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008 Nov; 327(2):442-52. View in: PubMed

  124. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 07; 7(7):568-74. View in: PubMed

  125. Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther. 2008 Dec; 84(6):691-7. View in: PubMed

  126. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics. 2008 Jun; 18(6):545-9. View in: PubMed

  127. Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. Mutagenesis. 2008 Sep; 23(5):341-6. View in: PubMed

  128. Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics. 2008 May; 9(5):489-92. View in: PubMed

  129. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8. View in: PubMed

  130. Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008 May; 82(5):1101-13. View in: PubMed

  131. The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights. 2008; 2:15-23. View in: PubMed

  132. On the challenges of the HapMap resource. Bioinformation. 2008 Jan 11; 2(6):238-9. View in: PubMed

  133. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008 Mar; 82(3):631-40. View in: PubMed

  134. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008 Mar; 18(3):253-62. View in: PubMed

  135. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9. View in: PubMed

  136. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8. View in: PubMed

  137. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007 Sep; 8(9):1159-68. View in: PubMed

  138. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37. View in: PubMed

  139. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007 Oct; 21(10):2128-36. View in: PubMed

  140. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res. 2007 Jul 15; 67(14):6889-98. View in: PubMed

  141. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007 Jun 01; 67(11):5425-33. View in: PubMed

  142. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9758-63. View in: PubMed

  143. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst). 2007 Aug 01; 6(8):1145-54. View in: PubMed

  144. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45. View in: PubMed

  145. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 01; 25(4):399-404. View in: PubMed

  146. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther. 2007 Jan; 6(1):31-6. View in: PubMed

  147. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 2007 May; 28(5):1111-6. View in: PubMed

  148. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 Feb; 33(1):9-23. View in: PubMed

  149. Genomes as geography: using GIS technology to build interactive genome feature maps. BMC Bioinformatics. 2006 Sep 19; 7:416. View in: PubMed

  150. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006 Jun; 32(4):261-76. View in: PubMed

  151. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9. View in: PubMed

  152. Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006 Jan 12; 71(3):239-47. View in: PubMed

  153. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46. View in: PubMed

  154. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87. View in: PubMed

  155. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005 Sep; 4(9):1364-8. View in: PubMed

  156. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55. View in: PubMed

  157. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics. 2005 Apr; 6(3):303-10. View in: PubMed

  158. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342. View in: PubMed

  159. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005 Jan 01; 65(1):46-53. View in: PubMed

  160. Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res. 2004 Nov; 101(2):97-106. View in: PubMed

  161. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics. 2004 Sep; 14(9):595-605. View in: PubMed

  162. 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Chem Res Toxicol. 2004 Sep; 17(9):1217-26. View in: PubMed

  163. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther. 2004 Sep; 3(9):1127-35. View in: PubMed

  164. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther. 2005 Jan; 312(1):206-13. View in: PubMed

  165. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6. View in: PubMed

  166. O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003 Dec; 25(12):941-7. View in: PubMed

  167. Temozolomide: realizing the promise and potential. Curr Opin Oncol. 2003 Nov; 15(6):412-8. View in: PubMed

  168. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther. 2003 Jul; 2(7):633-40. View in: PubMed

  169. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother Pharmacol. 2003 Oct; 52(4):291-302. View in: PubMed

  170. Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics. 2003 Jul; 13(7):425-35. View in: PubMed

  171. O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002 Sep; 1(11):943-8. View in: PubMed

  172. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Mol Cancer Ther. 2001 Nov; 1(1):21-8. View in: PubMed

  173. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):160-2. View in: PubMed

  174. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res. 2002 Aug; 8(8):2696-700. View in: PubMed

  175. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23. View in: PubMed

  176. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83. View in: PubMed

  177. Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies. Chem Res Toxicol. 2002 Mar; 15(3):380-7. View in: PubMed

  178. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7. View in: PubMed

  179. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec; 7(12):4239-44. View in: PubMed

  180. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. Stem Cells. 2001; 19(6):492-9. View in: PubMed

  181. Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporation. Bone Marrow Transplant. 2001 Jun; 27(11):1201-9. View in: PubMed

  182. Efficient expression of foreign genes in human CD34(+) hematopoietic precursor cells using electroporation. Gene Ther. 2001 Mar; 8(5):384-90. View in: PubMed

  183. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10. View in: PubMed

  184. Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism. Biochem Pharmacol. 2001 Mar 15; 61(6):721-6. View in: PubMed

  185. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice. Cancer Chemother Pharmacol. 2001; 47(1):63-9. View in: PubMed

  186. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000 Nov 15; 60(22):6307-10. View in: PubMed

  187. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000 Oct; 6(10):4154-7. View in: PubMed

  188. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000 Oct; 6(10):3870-7. View in: PubMed

  189. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000 Oct 01; 60(19):5464-9. View in: PubMed

  190. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000 Oct 15; 18(20):3522-8. View in: PubMed

  191. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9. View in: PubMed

  192. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000; 46(2):150-5. View in: PubMed

  193. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31. View in: PubMed

  194. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemother Pharmacol. 2000; 45(6):437-40. View in: PubMed

  195. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61. View in: PubMed

  196. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000 Mar 01; 60(5):1189-92. View in: PubMed

  197. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42. View in: PubMed

  198. Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Carcinogenesis. 1999 Dec; 20(12):2355-60. View in: PubMed

  199. Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20; 731(2):241-9. View in: PubMed

  200. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res. 1999 Aug; 5(8):2059-64. View in: PubMed

  201. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des. 1999 Aug; 5(8):587-605. View in: PubMed

  202. Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res. 1999 Jul 01; 59(13):3059-63. View in: PubMed

  203. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8. View in: PubMed

  204. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother Pharmacol. 1999; 43(1):80-5. View in: PubMed

  205. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13. View in: PubMed

  206. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998 Nov; 16(11):3570-5. View in: PubMed

  207. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res. 1995 Oct; 1(10):1133-8. View in: PubMed

  208. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47. View in: PubMed

  209. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs. 1998 Jun; 9(5):437-48. View in: PubMed

  210. O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases. Biochem Pharmacol. 1998 May 15; 55(10):1701-9. View in: PubMed

  211. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10. View in: PubMed

  212. Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol. 1998; 41(6):505-12. View in: PubMed

  213. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13. View in: PubMed

  214. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1997; 39(4):307-16. View in: PubMed

  215. Pharmacokinetics and metabolism in rats of 2,4-diamino-6-benzyloxy-5- nitrosopyrimidine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Drug Metab Dispos. 1996 Nov; 24(11):1205-11. View in: PubMed

  216. Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995 Dec; 23(12):1394-9. View in: PubMed

  217. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71. View in: PubMed

  218. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemother Pharmacol. 1996; 37(6):569-73. View in: PubMed

  219. Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol. 1996; 37(6):547-55. View in: PubMed

  220. Supplemental dietary calcium fails to alter the acute effects of 1,2-dimethylhydrazine on O6-methylguanine, O6-alkylguanine-DNA alkyltransferase and cellular proliferation in the rat colon. Carcinogenesis. 1993 Jun; 14(6):1175-9. View in: PubMed

  221. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993; 32(3):221-5. View in: PubMed

  222. The role of O6-alkylguanine-DNA alkyltransferase in protecting Rat4 cells against the mutagenic effects of O6-substituted guanine residues incorporated in codon 12 of the H-ras gene. Carcinogenesis. 1993 Apr; 14(4):593-8. View in: PubMed

  223. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(1):59-63. View in: PubMed

  224. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5. View in: PubMed

  225. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15; 53(18):4281-6. View in: PubMed

  226. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993 Jul 20; 46(2):285-90. View in: PubMed

  227. Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1994 Feb 04; 37(3):342-7. View in: PubMed

  228. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32(6):477-81. View in: PubMed

  229. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(6):471-6. View in: PubMed

  230. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry. 1993 Nov 16; 32(45):11998-2006. View in: PubMed

  231. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 1994 Sep 01; 54(17):4698-702. View in: PubMed

  232. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15; 54(16):4371-5. View in: PubMed

  233. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res. 1994 Jul 01; 54(13):3487-93. View in: PubMed

  234. Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol. 1994; 35(2):121-6. View in: PubMed

  235. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14. View in: PubMed

  236. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1994 Oct 01; 54(19):5123-30. View in: PubMed

  237. 8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1995 Jan 20; 38(2):359-65. View in: PubMed

  238. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994 Nov 29; 48(11):2127-34. View in: PubMed

  239. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995 Jul 01; 55(13):2853-7. View in: PubMed

  240. Metabolism and disposition of O6-benzyl-2'-deoxyguanosine in Sprague-Dawley rats. Chem Res Toxicol. 1994 Nov-Dec; 7(6):762-9. View in: PubMed

  241. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995; 51:167-223. View in: PubMed

  242. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26; 50(9):1385-9. View in: PubMed

  243. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol. 1995 Oct 12; 50(8):1141-8. View in: PubMed

  244. Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1984 Dec; 5(12):1641-7. View in: PubMed

  245. Comparison of repair of methylated pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli. Biochem Biophys Res Commun. 1984 Aug 30; 123(1):324-30. View in: PubMed

  246. Comparison of the rates of repair of O6-alkylguanines in DNA by rat liver and bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1984 Sep; 44(9):3806-11. View in: PubMed

  247. An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level. J Med Chem. 1983 Nov; 26(11):1656-9. View in: PubMed

  248. Depletion of O6-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1985 Dec; 6(12):1823-6. View in: PubMed

  249. Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines. Cancer Res. 1985 Dec; 45(12 Pt 1):6413-7. View in: PubMed

  250. Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem Biophys Res Commun. 1985 Oct 15; 132(1):178-85. View in: PubMed

  251. Extent of formation of O4-methylthymidine in calf thymus DNA methylated by N-methyl-N-nitrosourea and lack of repair of this product by rat liver O6-alkylguanine-DNA-alkyltransferase. Carcinogenesis. 1985 Nov; 6(11):1611-4. View in: PubMed

  252. Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ Health Perspect. 1985 Oct; 62:109-14. View in: PubMed

  253. Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and E. coli. Carcinogenesis. 1985 Jul; 6(7):1027-31. View in: PubMed

  254. Specificity of O6-alkylguanine-DNA alkyltransferase. IARC Sci Publ. 1987; (84):30-4. View in: PubMed

  255. Use of oligodeoxynucleotides containing O6-alkylguanine for the assay of O6-alkylguanine-DNA-alkyltransferase activity. Cancer Res. 1988 Mar 01; 48(5):1184-8. View in: PubMed

  256. Properties and assay of mammalian O6-alkylguanine-DNA alkyltransferase. Pharmacol Ther. 1987; 34(2):167-79. View in: PubMed

  257. Use of a dodecadeoxynucleotide to study repair of the O4-methylthymine lesion. Mutat Res. 1988 Mar; 193(2):131-7. View in: PubMed

  258. Sequence specificity of guanine alkylation and repair. Carcinogenesis. 1988 Nov; 9(11):2139-43. View in: PubMed

  259. Cell specific differences in O6-methylguanine-DNA methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells. Carcinogenesis. 1988 Nov; 9(11):2053-8. View in: PubMed

  260. Repair of O-alkylpyrimidines in mammalian cells: a present consensus. Proc Natl Acad Sci U S A. 1988 Mar; 85(6):1759-62. View in: PubMed

  261. Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res. 1986 Sep; 46(9):4500-4. View in: PubMed

  262. Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate. Cancer Res. 1988 Jul 01; 48(13):3603-6. View in: PubMed

  263. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis. 1989 Sep; 10(9):1613-9. View in: PubMed

  264. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8. View in: PubMed

  265. Intracellular activation of cytotoxic agents: kinetic models for methylnitrosoureas and N-methyl-N'-nitro-N-nitrosoguanidine in cell culture. Chem Res Toxicol. 1989 May-Jun; 2(3):157-61. View in: PubMed

  266. Investigation of the specificity of O6-alkylguanine-DNA-alkyltransferase. Chem Biol Interact. 1988; 65(3):275-81. View in: PubMed

  267. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990; 2(11):371-7. View in: PubMed

  268. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5368-72. View in: PubMed

  269. Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. Mutat Res. 1991 Sep-Oct; 250(1-2):397-409. View in: PubMed

  270. Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1991 Sep; 12(9):1679-83. View in: PubMed

  271. Production of antibodies to peptide sequences present in human O6-alkylguanine-DNA alkyltransferase and their use to detect this protein in cell extracts. Carcinogenesis. 1991 Sep; 12(9):1671-7. View in: PubMed

  272. Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine. Carcinogenesis. 1991 Dec; 12(12):2305-9. View in: PubMed

  273. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 01; 52(5):1171-5. View in: PubMed

  274. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72. View in: PubMed

  275. Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1992 Nov 13; 35(23):4486-91. View in: PubMed

  276. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16; 84(24):1926-31. View in: PubMed